FDA Panel Rejects Guerbet’s Imaging Drug Dotarem For Young Children
This article was originally published in The Pink Sheet Daily
Executive Summary
The gadolinium-based contrast agent should be approved for use in adults and older pediatric patients, but more data are needed to support a novel indication for children under two years old, the Medical Imaging Drugs Advisory Committee says.
You may also be interested in...
Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market
FDA advisory committee scheduled for Valentine’s Day is key test for Guerbet’s efforts to get its MRI imaging agent a wider indication than Bayer’s Gadavist.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.